Interleukin Genetics Inc

Type: Company
Name: Interleukin Genetics Inc
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Interleukin Genetics : PerioPredict® Receives 2014 DrBicuspid Dental Excellence Award

By a News Reporter-Staff News Editor at Health & Medicine Week -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict®, the Company's commercially available genetic risk test for periodontal ... [Published 4 Traders - Oct 22 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Genetic Risk Assessment for Periodontal Disease Highlighted during American Dental Association Annual Meeting

Dr. Kenneth S. Kornman of Interleukin Genetics Presents the Value and Use of Genetic Testing in Clinical Dentistry.Interleukin’s Genetic Risk Test, PerioPredict® Awarded “Best New Hygienist Product” by DrBicuspidDuring a Saturday morning continuing education ... [Published Oral Health Journal - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 5 reports

Interleukin’s PerioPredict Receives 2014 DrBicuspid Dental Excellence Award

WALTHAM, Mass.--( BUSINESS WIRE )-- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict ® , the Company’s commercially available genetic risk test for periodontal disease. PerioPredict ... [Published Citybizlist - Oct 13 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

TRACON Pharmaceuticals Expands Management Team and Board of Directors

Paul Walker is a partner in NEA's Menlo Park Office. He is a board observer of Sunesis and Interleukin Genetics, a former board member of TESARO (NASDAQ: TRSO), and manages a number of NEA's other late-stage and public investments.... ... [Published Town Hall - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 24 2014 - 1 reports

Tracon Pharmaceuticals racks up $27 mln Series B

Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo ... [Published PE Hub Blog - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 23 2014 - 3 reports

TRACON Pharmaceuticals, Inc. : TRACON Pharmaceuticals Completes $27 Million Fi...

TRACON Pharmaceuticals Completes $27 Million Financing and Expands Management Team and Board of Directors SAN DIEGO, Sept. 22, 2014 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization ... [Published Investegate - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 2 reports

Interleukin Genetics to Participate in Upcoming Investor and Scientific Events

Interleukin Genetics, Inc. ( OTCQB:ILIU ) announced today that Dr. KennethS. Kornman, Chief Executive Officer, will participate in the followingupcoming investor and scientific events:BTIG’s Inaugural Emerging Technologies in Healthcare DiagnosticsSymposium, ... [Published CBS Detroit - Sep 22 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 1 reports

Interleukin Genetics Reports Second Quarter 2014 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal second quarter ended June 30, 2014. “The utilization of our PerioPredict™ genetic test in the dental office is progressing ... [Published Business Wire Health News - Aug 13 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 1 reports

Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2014 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 13, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company’s second quarter ... [Published Business Wire Health News - Aug 06 2014]
First reported May 14 2014 - Updated May 14 2014 - 3 reports

Interleukin Genetics Reports First Quarter 2014 Financial Results

WALTHAM, Mass.--(EON: Enhanced Online News)--Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal first quarter ended March 31, 2014. “We are proud to report the achievement of multiple milestones so far ... [Published EON Business - May 14 2014]
First reported May 07 2014 - Updated May 07 2014 - 1 reports

Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2014 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Wednesday, May 14, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company’s first quarter ... [Published Business Wire Health News - May 07 2014]

Quotes

...Kornman . "We believe that PerioPredict® offers the potential to improve outcomes for dental patients and ultimately reduce long-term oral healthcare expenses. This award is a powerful endorsement of our product and it is very rewarding to see it be received so positively by our professional community."

More Content

All (21) | News (12) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Interleukin Genetics : PerioPredict® Receives 2... [Published 4 Traders - Oct 22 2014]
Genetic Risk Assessment for Periodontal Disease... [Published Oral Health Journal - Oct 14 2014]
Interleukin’s PerioPredict Receives 2014 DrBicu... [Published Citybizlist - Oct 13 2014]
Interleukin’s PerioPredict® Receives 2014 DrBic... [Published Investor's Business Daily - Oct 13 2014]
Interleukin’s PerioPredict® Receives 2014 DrBic... [Published Fort Mills Times - Oct 13 2014]
Interleukin’s PerioPredict® Receives 2014 DrBic... [Published Street Sweeper - Oct 13 2014]
Interleukin’s PerioPredict® Receives 2014 DrBic... [Published Business Wire Health News - Oct 13 2014]
TRACON Pharmaceuticals Expands Management Team ... [Published Town Hall - Sep 24 2014]
Tracon Pharmaceuticals racks up $27 mln Series B [Published PE Hub Blog - Sep 23 2014]
TRACON Pharmaceuticals, Inc. : TRACON Pharmaceu... [Published Investegate - Sep 22 2014]
TRACON Pharmaceuticals Completes and#36;27 Mill... [Published SPi World News - Sep 22 2014]
TRACON Pharmaceuticals Completes $27 Million Fi... [Published Franklin Credit Management Corporation - Sep 22 2014]
Interleukin Genetics to Participate in Upcoming... [Published CBS Detroit - Sep 22 2014]
Interleukin Genetics to Participate in Upcoming... [Published Business Wire Health News - Sep 22 2014]
Interleukin Genetics Reports Second Quarter 201... [Published Business Wire Health News - Aug 13 2014]
Interleukin Genetics, Inc. Announces Conference... [Published Business Wire Health News - Aug 06 2014]
Interleukin Genetics Reports First Quarter 2014... [Published EON Business - May 14 2014]
Interleukin Genetics Reports First Quarter 2014... [Published Business Wire Professional Services News - May 14 2014]
Interleukin Genetics Reports First Quarter 2014... [Published Business Wire Health News - May 14 2014]
Interleukin Genetics, Inc. Announces Conference... [Published Business Wire Health News - May 07 2014]
DNA-Based Dieting More Than Doubles Weight Loss... [Published PRWeb - Feb 10 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Interleukin’s PerioPredict® Receives 2014 DrBic... [Published Business Wire Health News - Oct 13 2014]
WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict®, the Company’s commercially available genetic risk test for periodontal disease. PerioPredict® ...
Tracon Pharmaceuticals racks up $27 mln Series B [Published PE Hub Blog - Sep 23 2014]
Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo ...
Interleukin Genetics to Participate in Upcoming... [Published Business Wire Health News - Sep 22 2014]
WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that Dr. Kenneth S. Kornman, Chief Executive Officer, will participate in the following upcoming investor and scientific events: BTIG’s Inaugural Emerging Technologies ...
Interleukin Genetics Reports Second Quarter 201... [Published Business Wire Health News - Aug 13 2014]
WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal second quarter ended June 30, 2014. “The utilization of our PerioPredict™ genetic test in the dental office is progressing ...
Interleukin Genetics, Inc. Announces Conference... [Published Business Wire Health News - Aug 06 2014]
WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 13, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company’s second quarter ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.